Fundraising FoxPsyMed Ventures — 2025 Investments
1 investments dated 2025 · listed companies and verified rows first · show all
Aerskaaerska.cominOct 2025
Aerska develops RNA interference (RNAi) medicines designed for targeted delivery across the blood-brain barrier to treat, delay, and prevent central nervous system and neurological diseases.
BiotechDeep TechHealthtechMedical Devices
Stuart Milstein(Chief Platform Officer, Co-founder)inJack O’Meara(Chief Executive Officer, Co-founder)inDave Hardwicke(Director, Head of Business Development, Co-founder)
Co-investorsage1BackedBlueYard CapitalEntrepreneur FirstGlobal Health Investment CorporationIaso Ventures+6 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.